Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Surgery
Published in: BMC Surgery 1/2022

Open Access 01-12-2022 | Sarcoma | Research

Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?

Authors: Jun Chen, Shi-Zhou Wu, Jie Tan, Qing-Yi Zhang, Bo-Quan Qin, Yu Wang, Hui Zhang

Published in: BMC Surgery | Issue 1/2022

Login to get access

Abstract

Background

Primary Ewing sarcoma (ES)/peripheral primitive neuroectodermal tumors (pPNETs) are aggressive bone tumors that rarely occur in the axial skeleton, including the cranial bone and mobile spine. The purpose of this study was to investigate whether there were any differences in patient characteristics, treatment strategies, and outcomes between patients with ES/pPNETs of the cranial bone and those with ES/pPNETs of the mobile spine.

Methods

A retrospective study was performed on 33 patients with ES/pPNETs who had been surgically treated and pathologically confirmed at our institution between 2010 and 2020. Patient characteristics were compared using Fisher exact tests or independent t tests. Survival rates were estimated via Kaplan–Meier survival analysis and compared using log-rank tests.

Results

Thirteen patients had ES/pPNETs of the cranial bone (39.4%), while 20 patients had ES/pPNETs of the mobile spine (60.6%). Patients with ES/pPNETs of the cranial bone had a younger mean age (14.8 vs 22.6 years; p = 0.047) and longer mean disease duration (2.5 vs 1.9 months; p = 0.008) compared with those of patients with ES/pPNETs of the mobile spine. Kaplan–Meier analysis showed that gross total resection (GTR) and radiotherapy resulted in a longer median survival time. The overall survival rates and progression-free survival rates of patients with ES/pPNETs of the cranial bone versus those of the mobile spine were not significantly different (p = 0.386 and p = 0.368, respectively).

Conclusions

Patients with ES/pPNETs of the cranial bone were younger compared to patients with ES/pPNETs of the mobile spine. There was no significant difference in the prognosis of patients with ES/pPNETs of the cranial bone versus those of the mobile spine. Taken together, our findings suggest that GTR and radiotherapy offer the best prognosis for improved long-term survival.
Literature
1.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.PubMed
2.
Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II Study 9457—a report from the Children’s Oncology Group. J Clin Oncol. 2006;24(1):152–9.PubMed
3.
4.
Arpaci E, Yetisyigit T, Seker M, Uncu D, Uyeturk U, Oksuzoglu B, Demirci U, Coskun U, Kucukoner M, Isikdogan A, et al. Prognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology. Med Oncol. 2013;30(1):469.PubMed
5.
Salunke PS, Gupta K, Malik V, Kumar N, Henke LE, Cai C, Chen WS, Pfeifer JD. Primary Ewing’s sarcoma of cranial bones: analysis of ten patients. Acta Neurochir (Wien). 2011;153(7):1477–85.
6.
Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108–14.PubMed
7.
Pilepich MV, Vietti TJ, Nesbit ME, Tefft M, Kissane J, Burgert O, Prichard D, Gehan EA. Ewing’s sarcoma of the vertebral column. Int J Radiat Oncol Biol Phys. 1981;7(1):27–31.PubMed
8.
Hobusch GM, Noebauer-Huhmann I, Krall C, Holzer G. Do long term survivors of ewing family of tumors experience low bone mineral density and increased fracture risk? Clin Orthop Relat Res. 2014;472(11):3471–9.PubMedPubMedCentral
9.
Hesla AC, Bruland OS, Jebsen N, Styring E, Eriksson S, Tsagozis P. Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years. J Bone Oncol. 2019;14: 100216.PubMed
10.
Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–46.
11.
Rodriguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM, Navid F. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies. Cancer. 2007;110(2):375–84.PubMed
12.
Weiss KR, Biau DJ, Bhumbra R, Griffin AM, Blackstein ME, Chung P, Catton C, O’Sullivan B, Ferguson PC, Wunder JS. Axial skeletal location predicts poor outcome in Ewing’s sarcoma: a single institution experience. Sarcoma. 2011;2011: 395180.PubMedPubMedCentral
13.
Hesla AC, Tsagozis P, Jebsen N, Zaikova O, Bauer H, Brosjo O. Improved prognosis for patients with Ewing sarcoma in the sacrum compared with the innominate bones: the Scandinavian Sarcoma Group Experience. J Bone Jt Surg Am. 2016;98(3):199–210.
14.
Martin E, Senders JT, Ter Wengel PV, Smith TR, Broekman MLD. Treatment and survival of osteosarcoma and Ewing sarcoma of the skull: a SEER database analysis. Acta Neurochir (Wien). 2019;161(2):317–25.
15.
Wan W, Lou Y, Hu Z, Wang T, Li J, Tang Y, Wu Z, Xu L, Yang X, Song D, et al. Factors affecting survival outcomes of patients with non-metastatic Ewing’s sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center. J Neurooncol. 2017;131(2):313–20.PubMed
16.
Martin E, Radomski S, Harley EH. Pediatric Ewing sarcoma of the head and neck: a retrospective survival analysis. Int J Pediatr Otorhinolaryngol. 2019;117:138–42.PubMed
17.
Mishra HB, Haran RP, Joseph T, Chandi SM. Primary Ewing’s sarcoma of the skull. A report of two cases. Br J Neurosurg. 1993;7(6):683–6.PubMed
18.
Marco RA, Gentry JB, Rhines LD, Lewis VO, Wolinski JP, Jaffe N, Gokaslan ZL. Ewing’s sarcoma of the mobile spine. Spine (Phila Pa). 2005;30(7):769–73.PubMed
19.
Choi SW, Shin SJ, Nam KW, Seo KB, Kim GM. Primary Ewing sarcoma of lumbar spine in an 8-year-old boy: a case report. J Pediatr Orthop B. 2012;21(4):322–4.PubMed
20.
Perry R, Gonzales I, Finlay J, Zacharoulis S. Primary peripheral primitive neuroectodermal tumors of the spinal cord: report of two cases and review of the literature. J Neurooncol. 2007;81(3):259–64.PubMed
21.
Muller K, Diez B, Muggeri A, Pietsch T, Friedrich C, Rutkowski S, von Hoff K, von Bueren AO, Zwiener I, Bruns F. What’s in a name? Intracranial peripheral primitive neuroectodermal tumors and CNS primitive neuroectodermal tumors are not the same. Strahlenther Onkol. 2013;189(5):372–9.PubMed
22.
Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, Weiss SW. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29(8):1025–33.PubMed
23.
Arshi A, Sharim J, Park DY, Park HY, Yazdanshenas H, Bernthal NM, Shamie AN. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine. Spine J. 2017;17(5):645–55.PubMed
24.
Bhattacharjee S, Venkata SR, Uppin MS. Skull and spinal Ewing’s sarcoma in children: an institutional study. J Pediatr Neurosci. 2018;13(4):392–7.PubMedPubMedCentral
25.
Hrabalek L, Kalita O, Svebisova H, Ehrmann J Jr, Hajduch M, Trojanec R, Kala M. Dumbbell-shaped peripheral primitive neuroectodermal tumor of the spine—case report and review of the literature. J Neurooncol. 2009;92(2):211–7.PubMed
26.
Marmonti E, Savage H, Zhang A, Bedoya CAF, Morrell MG, Harden A, Buzbee M, Schadler K. Modulating sphingosine-1-phosphate receptors to improve chemotherapy efficacy against Ewing sarcoma. Int J Cancer. 2020;147(4):1206–14.PubMed
27.
Mirzaei L, Kaal SE, Schreuder HW, Bartels RH. The neurological compromised spine due to Ewing sarcoma. What first: surgery or chemotherapy? Therapy, survival, and neurological outcome of 15 cases with primary Ewing sarcoma of the vertebral column. Neurosurgery. 2015;77(5):718–24 (discussion 724-715).PubMed
28.
Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing’s sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009;10(1–2):126–40.PubMed
29.
Gomez-Brouchet A, Mascard E, Siegfried A, de Pinieux G, Gaspar N, Bouvier C, Aubert S, Marec-Berard P, Piperno-Neumann S, Marie B, et al. Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS). Orthop Traumatol Surg Res. 2019;105(4):773–80.PubMed
30.
DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, Shamberger RC, Sailer S, Nicholas RW, Healey JH, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children’s Oncology Group. Cancer. 2015;121(3):467–75.PubMed
31.
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, Peake D, Seddon B, Whelan J, British Sarcoma G. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7.PubMedPubMedCentral
32.
Work EESN. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:100–9.
33.
Rodriguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, Krasin MJ. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008;19(4):814–20.PubMed
34.
Donati D, Yin JQ, Di Bella C, Colangeli M, Bacci G, Ferrari S, Bertoni F, Barbieri E, Mercuri M. Local and distant control in non-metastatic pelvic Ewing’s sarcoma patients. J Surg Oncol. 2007;96(1):19–25.PubMed
35.
Bacci G, Toni A, Avella M, Manfrini M, Sudanese A, Ciaroni D, Boriani S, Emiliani E, Campanacci M. Long-term results in 144 localized Ewing’s sarcoma patients treated with combined therapy. Cancer. 1989;63(8):1477–86.PubMed
36.
Wilkins RM, Pritchard DJ, Burgert EO Jr, Unni KK. Ewing’s sarcoma of bone. Experience with 140 patients. Cancer. 1986;58(11):2551–5.PubMed
37.
Kerr DL, Dial BL, Lazarides AL, Catanzano AA, Lane WO, Blazer DG 3rd, Brigman BE, Mendoza-Lattes S, Eward WC, Erickson ME. Epidemiologic and survival trends in adult primary bone tumors of the spine. Spine J. 2019;19(12):1941–9.PubMed
38.
Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(3):334–8.PubMedPubMedCentral
39.
Fuchs B, Valenzuela RG, Sim FH. Pathologic fracture as a complication in the treatment of Ewing’s sarcoma. Clin Orthop Relat Res. 2003;415:25–30.
40.
Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.PubMed
41.
Cangir A, Vietti TJ, Gehan EA, Burgert EO Jr, Thomas P, Tefft M, Nesbit ME, Kissane J, Pritchard D. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer. 1990;66(5):887–93.PubMed
42.
43.
Ren Y, Zhang Z, Shang L, You X. Surgical resection of primary Ewing’s sarcoma of bone improves overall survival in patients presenting with metastasis. Med Sci Monit. 2019;25:1254–62.PubMedPubMedCentral
Metadata
Title
Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?
Authors
Jun Chen
Shi-Zhou Wu
Jie Tan
Qing-Yi Zhang
Bo-Quan Qin
Yu Wang
Hui Zhang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2022
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-021-01452-4

Other articles of this Issue 1/2022

BMC Surgery 1/2022 Go to the issue

Case report

Oral extrusion of a vertebral body replacement device after chordoma tumor growth and radiation: case report and review

Research article

Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma

Research article

Transannular patch repair of tetralogy of Fallot with or without monocusp valve reconstruction: a meta-analysis

Research

Short-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma in older patients: a propensity score matching analysis

Research

Hand-assisted laparoscopic resection versus total laparoscopic gastric surgery for primary gastric gastrointestinal stromal tumors (GISTs): an analysis from a high-volume institution

Research article

The clinical effectiveness and complications of lumbar selective fenestration and concave-side fusion (LSFCF) in degenerative lumbar scoliosis (DLS) combined with lumbar spinal stenosis (LSS)